Citations

Clear

9383 citation(s) found for "Thomas, PS".

Timing to Administration and Ease of Dosing of Diazepam Nasal Spray Rescue Therapy for Seizure Clusters: Results From a Phase 3, Long-Term Open-Label, Repeat-Dose Safety Study (P15-8.001)
Desai, Jay , Liow, Kore , Dlugos, Dennis , Cascino, Gregory, Hogan, R Edward , Wheless, James W. , Sperling, Michael R. , Tarquinio, Daniel Charles , Misra, Sunita N. , Rabinowicz, Adrián L. , Carrazana, Enrique

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1655 Get It

Safety of a Second Dose of Diazepam Nasal Spray Within 4 Hours in Patients With Seizure Clusters: Final Results From a Long-Term, Phase 3, Open-Label, Repeat-Dose Safety Study (P14-8.003)
Cascino, Gregory, Desai, Jay , Tarquinio, Daniel Charles , Wheless, James W. , Hogan, R Edward , Sperling, Michael R. , Liow, Kore , Misra, Sunita N. , Rabinowicz, Adrián L. , Carrazana, Enrique

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1605 Get It

Post-hoc Analysis of Safety in Phase 3 Atogepant ADVANCE Trial Participants with or without Cardiovascular Disease Risk Factors (P2-2.005)
Blumenfeld, Andrew , Pavlović, Jelena , Best, Patricia J.M. , Ma, Julia, Smith, Jonathan H., Severt, Lawrence, Dabruzzo, Brett , Hutchinson, Susan R. , Pavlovic, Jelena M. , Monteith, Teshamae , Nahas, Stephanie J.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1583 Get It

Characterizing Pre-headache (Prodrome) Features of Migraine Attacks: Results From the CaMEO Study (S4.004)
Fanning, Kristina M. , Lama, Janette Contreras‐De, Jordan, Brittany L., Reed, Michael L. , Buse, Dawn C. , Schwedt, Todd J. , Nahas, Stephanie J. , Jordan, Brittany, Lipton, Richard B.

Mayo Clinic

Neurology | December 6, 2023 | Volume: 98 | Issue: 18_supplement | Pages: No page available

10.1212/wnl.98.18_supplement.1208 Get It

The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease
Swaminathan, Akhilesh , Fulforth, James , Frampton, Chris , Borichevsky, Grace M , Mules, Thomas , Kilpatrick, Kate, Choukour, Myriam, Fields, Peter A. , Ramkissoon, Resham­ , Helms, Emily G., Leong, Rupert W. , Mules, Thomas C , Siegel, Corey A , Leong, Rupert W , Kilpatrick, Kate, Fields, Peter, Hanauer, Stephen B. , Peyrin‐Biroulet, Laurent , Gearry, Richard B.

Mayo Clinic

Inflammatory Bowel Diseases | December 5, 2023 | Volume: 30 | Issue: 11 | Pages: 2064-2075

10.1093/ibd/izad294 | PMID 38134391 Get It

Abstract Background The disease severity index (DSI) for inflammatory bowel disease (IBD) combines measures of disease phenotype, inflammatory activity, and patient-reported outcomes. We aimed to validate the DSI and assess its utility in predicting a complicated IBD course. Methods A multicenter cohort of adults with IBD was recruited. Intraclass correlation coefficients (ICCs) and weighted Kappa assessed inter-rater reliability. Cronbach’s alpha measured internal consistency of DSI items. Spearman’s rank correlations compared the DSI with endoscopic indices, symptom indices, quality of life, and disability. A subgroup was followed for 24 months to assess for a complicated IBD course. Area under the receiver operating characteristics curve (AUROC) and multivariable logistic regression assessed the utility of the DSI in predicting disease progression. Results Three hundred and sixty-nine participants were included (Crohn’s disease [CD], n = 230; female, n = 194; mean age, 46 years [SD, 15]; median disease duration, 11 years [interquartile range, 5-21]), of which 171 (CD, n = 99; ulcerative colitis [UC], n = 72) were followed prospectively. The DSI showed inter-rater reliability for CD (ICC 0.93, n = 65) and UC (ICC 0.97, n = 33). The DSI items demonstrated inter-rater agreement (Kappa > 0.4) and internal consistency (CD, α > 0.59; UC, α > 0.75). The DSI was significantly associated with endoscopic activity (CDn=141, r = 0.65, P < .001; UCn=105, r = 0.80, P < .001), symptoms (CDn=159, r = 0.69, P < .001; UCn=132, r = 0.58, P < .001), quality of life (CDn=198, r = −0.59, P < .001; UCn=128, r = −0.68, P < .001), and disability (CDn=83, r = −0.67, P < .001; UCn=52, r = −0.74, P < .001). A DSI of 23 best predicted a complicated IBD course (AUROC = 0.82, P < .001) and was associated with this end point on multivariable analyses (aOR, 9.20; 95% confidence interval, 3.32-25.49). Conclusions The DSI reliably encapsulates factors contributing to disease severity and accurately prognosticates the longitudinal IBD course.
Senotherapeutic drug treatment ameliorates chemotherapy-induced cachexia
Englund, Davis A. , Jolliffe, Alyssa M. , Hanson, Gabriel J., Aversa, Zaira, Zhang, Xu , White, Thomas A. , Zhang, Lei , Monroe, David G. , Niedernhofer, Laura J. , Jiang, Xinyi, Monroe, David G , Niedernhofer, Laura J , White, Thomas A , Zhang, Xu , Zhang, Lei , Englund, Davis A. , Jiang, Xinyi , Robbins, Paul D. , Kamenecka, Theodore M. , Khosla, Sundeep , LeBrasseur, Nathan K.

Mayo Clinic

JCI Insight | December 5, 2023 | Volume: 9 | Issue: 2 | Pages: No page available

10.1172/jci.insight.169512 | PMID 38051584 Get It

Cachexia is a debilitating skeletal muscle wasting condition for which we currently lack effective treatments. In the context of cancer, certain chemotherapeutics cause DNA damage and cellular senescence. Senescent cells exhibit chronic activation of the transcription factor NF-κB, a known mediator of the proinflammatory senescence-associated secretory phenotype (SASP) and skeletal muscle atrophy. Thus, targeting NF-κB represents a logical therapeutic strategy to alleviate unintended consequences of genotoxic drugs. Herein, we show that treatment with the IKK/NF-κB inhibitor SR12343 during a course of chemotherapy reduces markers of cellular senescence and the SASP in liver, skeletal muscle, and circulation and, correspondingly, attenuates features of skeletal muscle pathology. Lastly, we demonstrate that SR12343 mitigates chemotherapy-induced reductions in body weight, lean mass, fat mass, and muscle strength. These findings support senescent cells as a promising druggable target to counteract the SASP and skeletal muscle wasting in the context of chemotherapy.
Exploring the genetics of lithium response in bipolar disorders
Adli, Mazda , Akiyama, Kazufumi , Akula, Nirmala , Amare, Azmeraw T. , Ardau, Raffaella , Aubry, Jean‐Michel , Benabarre, Antonio , Bengesser, Susanne , Bhattacharjee, Abesh Kumar, Birner, Armin , Cearns, Micah , Cervantes, Pablo , Chillotti, Caterina , Cichon, Sven , Clark, Scott R. , Cruceanu, Cristiana , Dalkner, Nina , Zompo, Maria Del , Ferensztajn‐Rochowiak, Ewa , Forstner, Andreas J. , Frank, Josef , Frisén, Louise , Frye, Mark A. , Gard, Sébastien, Grof, Paul , Hsu, Yi‐Hsiang, Kahn, Jean‐Pierre, Kassem, Layla, Kittel‐Schneider, Sarah , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leckband, Susan G. , Maj, Mario , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , O’Donovan, Claire , Pfennig, Andrea , Pisanu, Claudia , Potash, James B. , Richard-Lepouriel, Hélène , Roberts, Gloria , Schalling, Martin , Schubert, Klaus Oliver , Schulte, Eva C. , Schweizer, Barbara , Severino, Giovanni , Shekhtman, Tatyana , Shilling, Paul D. , Shimoda, Katzutaka, Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Streit, Fabian , Veeh, Julia, Witt, Stephanie H. , Zandi, Peter P. , Bauer, Michael , Witt, Stephanie H , Cichon, Sven , Amare, Azmeraw , Cruceanu, Cristiana , Schulte, Eva , Kittel-Schneider, Sarah , Lavebratt, Catharina , McCarthy, Michael , Pisanu, Claudia , Schubert, Klaus Oliver , Streit, Fabian , Mitjans, Marina , Herrera-Rivero, Marisol , Arias, Bárbara , Aubry, Jean‐Michel , Backlund, Lena , Bellivier, Frank , Biernacka, Joanna M. , Chen, Hsi‐Chung , Colom, Francesc , Czerski, Piotr M. , Dalkner, Nina , Degenhardt, Franziska , DePaulo, J Raymond , Étain, Bruno , Falkai, Peter , Fullerton, Janice M. , Gallo, Carla , Garnham, Julie , Goes, Fernando , Grigoroiu‐Serbânescu, Maria , Hashimoto, Ryota , Hasler, Roland , Hauser, Joanna , Heilbronner, Urs , Herms, Stefan , Hoffmann, Per , Hou, Liping , Jamain, Stéphane , Jiménez, Esther , Kato, Tadafumi , Kelsoe, John R , Kuo, Po‐Hsiu , Kusumi, Ichiro , König, Barbara , Leboyer, Marion , Manchia, Mirko , Marie-Claire, Cynthia , Martinsson, Lina , McElroy, Susan L. , Millischer, Vincent , Monteleone, Palmiero , Nievergelt, Caroline M , Novák, Tomáš , Nöthen, Markus M. , Ozaki, Norio , Papiol, Sergi , Reif, Andreas , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Schofield, Peter R. , Squassina, Alessio , Stopková, Pavla , Tekola‐Ayele, Fasil , Thalamuthu, Anbupalam , Tortorella, Alfonso , Turecki, Gustavo , Vieta, Eduard , Viswanath, Biju , Alda, Martin , McMahon, Francis J. , Mitchell, Philip B , Rietschel, Marcella , Schulze, Thomas , Baune, Bernhard

Mayo Clinic

No container title available | December 2, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3677630/v1 | PMID 38077040 Get It

Abstract Background: Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP. It also has been shown to have beneficial effects on disease-associated conditions, including sleep and cardiovascular disorders. However, the individual responses to Li treatment vary within and between diagnostic subtypes of BP (e.g. BP-I and BP-II) according to the clinical presentation. Moreover, long-term Li treatment has been linked to adverse side-effects that are a cause of concern and non-adherence, including the risk of developing chronic medical conditions such as thyroid and renal disease. In recent years, studies by the Consortium on Lithium Genetics (ConLiGen) have uncovered a number of genetic factors that contribute to the variability in Li treatment response in patients with BP. Here, we leveraged the ConLiGen cohort (N=2,064) to investigate the genetic basis of Li effects in BP. For this, we studied how Li response and linked genes associate with the psychiatric symptoms and polygenic load for medical comorbidities, placing particular emphasis on identifying differences between BP-I and BP-II. Results: We found that clinical response to Li treatment, measured with the Alda scale, was associated with a diminished burden of mania, depression, substance and alcohol abuse, psychosis and suicidal ideation in patients with BP-I and, in patients with BP-II, of depression only. Our genetic analyses showed that a stronger clinical response to Li was modestly related to lower polygenic load for diabetes and hypertension in BP-I but not BP-II. Moreover, our results suggested that a number of genes that have been previously linked to Li response variability in BP differentially relate to the psychiatric symptomatology, particularly to the numbers of manic and depressive episodes, and to the polygenic load for comorbid conditions, including diabetes, hypertension and hypothyroidism. Conclusions: Taken together, our findings suggest that the effects of Li on symptomatology and comorbidity in BP are partially modulated by common genetic factors, with differential effects between BP-I and BP-II.
Molecular Findings on Plasma Cell-Free DNA Analysis Among Adults with Histiocytic Neoplasms
Medina, Aldo Adrian Acosta, Abeykoon, Jithma P. , Zanwar, Saurabh , Efremov, Aleksei, Sookiasian, Danielle , Tazearslan, Cagdas, Yudina, Anastasia, Ruan, Gordon , Jiang, Liuyan , Gruber, Lucinda , Davidge‐Pitts, Caroline , Dasari, Surendra , Goyal, Gaurav , Rech, Karen L. , Ravindran, Aishwarya , Koster, Matthew J. , Tobin, W. Oliver , Vassallo, Robert , Ryu, Jay H. , Bennani, N. Nora , Shah, Meera , Witzig, Thomas E. , Young, Jason R. , Go, Ronald S.

Mayo Clinic

Blood | December 2, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 6332-6332

10.1182/blood-2023-187500 Get It

Introduction The discovery of MAPK/ERK pathway mutations has revolutionized the care for patients with histiocytic neoplasms. However, mutational analysis on biopsy specimens is often limited by low tumor cellularity leading to testing failure or disease involvement of difficult-to-reach sites (e.g., central nervous system). Recently, molecular analysis of cell-free DNA (cfDNA) has shown promise as a viable tool for discovering driver mutations in multiple cancers. A recent study of mainly BRAF-mutated non-Langerhans cell histiocytosis (LCH) showed 50% concordance between tumor and plasma cfDNA analysis for BRAF-V600E. However, it is unknown whether cfDNA has a role in the evaluation of cases that harbor mutations beyond BRAF-V600E. We conducted this study to address this unanswered question using a large cohort of individuals with diverse histiocytic neoplasms from a tertiary-care institution. Methods We included 40 cases with histiocytic neoplasms with stored plasma and germline DNA in this study. Tissue molecular analysis was conducted using a targeted next generation sequencing (NGS) using commercial assays or whole exome sequencing (WES) using an in-house assay. A custom panel of 226 genes, including exonic and intronic regions, was used for the cfDNA assay in this study. To avoid cfDNA false positives, germline mutations identified from normal DNA sequencing were filtered using a BostonGene ®-developed error reduction algorithm.The total length of the analyzed genomic regions was 1.56 MB. For samples with an input greater than 30 ng, a 0.2% variant allele frequency (VAF) limit of detection (LOD) was used; a 0.4% VAF LOD was used for samples less than 30 ng. Results The final analysis cohort included 38 patients with histiocytic neoplasms after exclusion of 2 cases (failure of germline DNA library preparation and mismatch of germline and somatic DNA, respectively). Disease types included Erdheim-Chester disease (ECD; n=13, 34%), Langerhans cell histiocytosis (LCH; n=13, 34%), and Rosai-Dorfman disease (RDD; n=12, 32%). 24 cases were multisystem (63%), and the remaining were single-system. Commonly involved organs included bone (n=25, 66%), kidney (n=12, 32%), skin (n=8, 21%), central nervous system (n=7, 18%), and pituitary (n=7, 18%). Most cases (n=31, 82%) underwent plasma collection pre-treatment, 5 cases underwent collection after histiocytosis-directed therapy, and 2 while on treatment. Tissue NGS/WES data were available for 28 (74%) cases; 5 cases (13%) had insufficient tissue cellularity, and 5 (13%) did not undergo any tissue sequencing. Among those who underwent successful tissue sequencing assays, the most common common driver alterations was BRAF V600E (n=5, 26%). Other alterations included those in MAP2K1 (n=4, 21%), BRAF-fusions (n=3, 10%; partners UBDT2, RNF11, and LMTK2, respectively), and single cases of KRAS, NRAS and BRAF indel, respectively. cfDNA analysis showed at least one variant in 23 cases (60%). Correlation between tissue and cfDNA for known driver mutations was poor and concordant findings were only seen in one case with ECD harboring BRAF V600E in tissue as well as plasma (VAF 0.5%). Among the 5 cases where tissue mutational analysis had failed, cfDNA showed mutations in MUTYH, PTCH2, NOTCH3 SDHD, and TMEM127, respectively (Figure 1). Among the 5 cases where tissue molecular assessment could not be undertaken due to various reasons, cfDNA showed alterations in 4 cases, encompassing NOTCH1, TET2, BRCA1, MSH6, PIK3CD, and FUS genes. Conclusions In a large cohort of adults with diverse histiocytic neoplasms, we found poor correlation between tumor and plasma cfDNA molecular findings. The reason for the lack of correlation may be related to low tumor shedding especially among non- BRAF V600E cases. cfDNA analysis may have a role to identify potential drivers of pathogenesis among cases that are unable to successfully undergo tissue molecular analysis. Further studies are underway to characterize other novel alterations that were discovered in the cfDNA analysis.
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in Patients (pts) with Triple-Class-Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): Analysis of Cytopenias and Infections in Pts from KarMMa-3
Arnulf, Bertrand , Patel, Krina K. , Abrahamsen, Ingerid Weum , Delforge, Michel , Sborov, Douglas W. , Ishida, Tadao, Varshavsky‐Yanovsky, Asya, Choi, Taewoong , Truppel-Hartmann, Anna, Bhatnagar, Rashmi, Piasecki, Julia , Felten, Jasper, Caia, Andrea, Abrahamsen, Ingerid Weum , Baz, Rachid , Rodríguez‐Otero, Paula , Ailawadhi, Sikander , Nooka, Ajay K. , Costa, Luciano J. , Raje, Noopur , Gergis, Usama , Giralt, Sergio , Raab, Marc S. , Ishida, Tadao , Anderson, Larry D. , Wu, Fan , Cook, Mark , Lin, Yi

Mayo Clinic

Blood | December 2, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 4879-4879

10.1182/blood-2023-174477 Get It

Introduction In the KarMMa-3 trial (NCT03651128), ide-cel, a BCMA-directed CAR T cell therapy (Tx), significantly improved median progression-free survival (13.3 vs 4.4 mo, HR 0.49, P < 0.001) and overall response rate (71% vs 42%, P < 0.001) vs std regimens in pts with RRMM who were TCE to immunomodulatory (IMiD ®) agents, proteasome inhibitors (PIs), and daratumumab (Rodríguez-Otero NEJM 2023). Early high-grade (gr) cytopenias and severe infections have been reported post-CAR T cell infusion (Logue Blood 2022, Thibaud Blood 2022), and persistent cytopenias and infections can pose clinical challenges in pt care. In this safety analysis of KarMMa-3, we report frequency, kinetics of occurrence, and management of cytopenias and infections post-Tx with ide-cel or std regimens. Methods This international, randomized, multicenter phase 3 trial enrolled pts with RRMM who received 2-4 prior Txs (an IMiD agent, a PI, and daratumumab) and were refractory to the last Tx. Pts were randomized 2:1 to ide-cel or a std regimen (DPd, DVd, IRd, Kd, or EPd) selected by investigator based on prior anti-MM Tx. In the ide-cel arm, pts could have ≤ 1 cycle of optional bridging Tx (BTx) for disease control. Treated population (pop; ide-cel: pts who received leukapheresis [LA], BTx, lymphodepleting chemotherapy, or ide-cel; std regimens: pts who received any dose of study Tx) was used to assess adverse events (AEs), gr 3/4 AEs, and serious AEs. Safety pop (pts who received ide-cel or any dose of std regimens) was used to assess treatment-emergent AEs, AEs of special interest, investigator-identified neurotoxicity/cytokine release syndrome and others. In pts who had documented disease progression on std regimens and then underwent LA to receive ide-cel, only AEs before LA were included. In this analysis, incidence of cytopenias and infections at various time intervals and management, types of infections, and incidence of hypogammaglobulinemia (HGG) were assessed. Results At data cutoff (Oct 3, 2022), median follow-up was 24.1 (range 5.9−41.0) mo in the 386 randomized pts. In the treated pop, 248/249 (99.6%) vs 124/126 (98.4%) pts had any-gr AEs, 234 (94.0%) vs 96 (76.2%) had gr 3/4, and 36 (14.5%) vs 9 (7.1%) had gr 5 in ide-cel vs std regimens arms, respectively. Of the gr 5 AEs, 18/36 and 3/9 had verbatim terms consistent with progressive disease. In the safety pop, incidence of gr 3/4 cytopenias with ide-cel were higher early after infusion but generally resolved over time (196 [87.1%] pts at < 3 mo, 52 [24.1%] pts at 3−< 6 mo, 30 [14.7%] pts at ≥ 6 mo; Table 1) vs std regimens, which showed lower rate of resolution over time. More pts in the ide-cel (16 [7.1%]) vs std regimens arms (3 [2.4%]) had any-gr febrile neutropenia. Cytopenias were mainly managed using colony-stimulating factor in both arms (55.5% and 58.7%, respectively); RBC (48%) and platelet transfusions (32%) were more common in the ide-cel arm. Overall, incidence of gr 3/4 infections was high at < 3 mo and remained consistent over time in both arms (ide-cel: 17 [7.6%] pts at < 3 mo, 18 [8.3%] pts at 3−< 6 mo, 13 [6.4%] pts at ≥ 6 mo; Table 2). Any-gr bacterial infections were more common in the ide-cel vs std regimens arms with higher incidence at < 3 mo (10% vs 6%) but lowered at later timepoints. Incidence of gr ≥ 3 viral infections remained low and consistent with time; fungal infections were uncommon. Deaths due to infections occurred in 3 (1.3%) vs 1 (0.8%) pts at < 3 mo, 0 pts at 3−< 6 mo, and 7 (3.4%) vs 2 (2.6%) pts at ≥ 6 mo in the ide-cel vs std regimens arms, respectively. Indence of any-gr new HGG was higher in the ide-cel vs std regimens arms but decreased over time: 15 (6.7%) vs 2 (1.6%) pts at < 3 mo, 3 (1.4%) vs 1 (0.9%) at 3−< 6 mo, and 5 (2.5%) vs 0 at ≥ 6 mo, respectively; of these, 13 (5.8%) vs 1 (0.8%), 2 (0.9%) vs 1 (0.9%), and 5 (2.5%) vs 0 pts received IV immunoglobulin replacement Tx at the respective time intervals. Incidence rate (% per 100 pt-years, 95% CI) of second primary malignancies remained low and similar between arms (ide-cel, 4.0 [2.4−6.7]; std regimens, 4.4 [1.9−10.7]). Conclusion In KarMMa-3, most severe cytopenias associated with ide-cel occurred early, with a low incidence of prolonged cytopenias; all were largely manageable. Any-gr bacterial infections decreased over time while viral infections remained the same. No new safety concerns were identified for ide-cel; safety profile was consistent with previous reports. Study support 2seventy bio and Celgene, a Bristol-Myers Squibb Company.
Incidence of Central Nervous System Relapse in Patients with Primary Mediastinal Large B-Cell Lymphoma: A Retrospective Study
Okcu, Izel, Thanarajasingam, Gita , Johnston, Patrick B. , Bock, Allison M. , Baidoun, Firas, Nowakowski, Grzegorz S. , Okcu, Izel , Zhou, Jihao , Wang, Yucai , Habermann, Thomas M. , Witzig, Thomas E. , Rimsza, Lisa M. , Baidoun, Firas , Moustafa, Muhamad Alhaj

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 6279-6279

10.1182/blood-2023-189778 Get It

Background Primary mediastinal large B-cell lymphoma (PMBCL) is an uncommon type of non-Hodgkin lymphoma. Clinicopathologic features are distinct from diffuse large B cell lymphoma, but it shares some clinical and biologic features with Nodular sclerosis classic Hodgkin lymphoma. Central nervous system (CNS) relapse appears to be rare in patients with PMBCL, with limited literature reporting a rate of approximately 1.5% to 4%. We examined the incidence of CNS relapse, treatment approaches and survival outcomes in patients with PMBCL. Methods Patients with newly diagnosed PMBCL seen at Mayo Clinic between 2002 and 2022 were identified using the prospective Mayo Clinic Lymphoma Database. Clinical features, treatment details and outcomes were abstracted from the medical record. Cumulative incidence of CNS relapse was analyzed with death as a competing risk. The association of CNS-IPI, systemic treatment, and CNS prophylaxis approach with CNS relapse rate was analyzed using competing risk models and descriptively. Event-free survival (EFS) for the cohort was defined as time from PMBCL diagnosis to first recorded CNS and/or systemic relapse or death from any cause. Overall survival (OS) was defined as time from PMBCL diagnosis (or CNS relapse) to death from any cause. Survival analysis was performed using the Kaplan-Meier method. Results A total of 124 PMBCL cases were identified. The median age at diagnosis was 37 years and 61% were female. The distribution of CNS-IPI was low-risk in 67 (61%), intermediate-risk in 41 (37%), and high-risk in 2 (2%). 64 patients (52%) received R-CHOP and 54 patients (44%) received R-DA-EPOCH as frontline therapy. High-dose methotrexate (HD-MTX) for CNS prophylaxis was administered to 6 patients (5%), 5 with R-CHOP and 1 with R-DA-EPOCH. 16 patients received intrathecal (IT) chemotherapy (methotrexate and/or cytarabine) for CNS prophylaxis, 3 with R-CHOP and 13 with R-DA-EPOCH. The median follow-up was 56.0 months. The 5-year EFS rate was 75.1% and the 5-year OS rate was 90.7% for the entire cohort. 20 patients had systemic relapse only and 3 had CNS relapse. The cumulative incidence of CNS relapse was 1.84% (95% CI 0.46%-7.17%) at 2 years and 2.92% (95% CI 0.50%-8.84%) at 5 years (Figure 1). No statistically significant association of CNS-IPI, systemic therapy or CNS prophylaxis regimen with CNS relapse rate was found in competing risk models; however, this analysis was limited by a small event number (n=3). Among the 3 patients with CNS relapse, 1 had high-risk CNS-IPI and 2 had intermediate risk. All 3 patients were treated initially with R-CHOP. Two patients did not receive any CNS prophylaxis and 1 patient received IT CNS prophylaxis. All three patients who had CNS relapse were female. Patient #1 was diagnosed at age 48 and had simultaneous CNS and systemic relapse 6 months later. The patient was treated with HD-MTX, temozolomide and rituximab for CNS relapse, and subsequently received multiple therapies for systemic disease including R-DHAP, R-ICE, and died 17 months after CNS relapse. Patient #2 was diagnosed at age 22 and had CNS relapse after 8.7 months, followed by systemic relapse 2 months later. The patient received HD-MTX, temozolomide and rituximab for CNS relapse, followed by systemic and whole-brain radiation therapy (RT) for both systemic and CNS relapse. Subsequently the patient received salvage chemotherapy, autologous and allogeneic stem cell transplant for systemic relapse. The patient died 26.8 months after CNS relapse. Patient #3 was diagnosed at age 24 and had systemic relapse after 20.7 months, followed by CNS relapse 5.4 months later. The patient received methotrexate and whole-brain RT following CNS relapse and died 1.2 months after CNS relapse. Besides these 3 patients, we identified 6 PMBCL patients with CNS relapse who were diagnosed at other medical centers and subsequently referred to our institution for management of refractory disease. The survival after CNS relapse was poor, with a median OS of 10.4 months (95% CI 5.6-15.2). Conclusion Our study showed that the CNS relapse rate (1.84% at 2 years and 2.92% at 5 years) was overall low in patients with PMBCL, consistent with previous reports. CNS relapse was associated with poor survival despite aggressive treatment approaches. Novel approaches utilizing biological risk factors for CNS relapse, such as circulating tumor DNA, are needed to identify patients with CNS relapse.